Kodiak Sciences Inc. Cash Flow Statement
KOD / Health Care|9 years of annual SEC 10-K data (FY2016-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
Kodiak Sciences Inc. used $117M in operating cash flow and negative free cash flow of $118M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$176.2M | -$260.5M | -$333.8M | -$267.0M | -$133.1M | -$47.4M | -$41.4M | -$27.9M | -$17.1M |
| Depreciation & Amortization | $18.7M | $18.3M | $3.8M | $1.0M | $477.0K | $538.0K | $490.0K | $549.0K | $257.0K |
| Operating Cash Flow | -$117.3M | -$154.2M | -$206.5M | -$182.3M | -$83.4M | -$39.1M | -$29.0M | -$17.7M | -$16.0M |
| Capital Expenditures | $375.0K | $41.4M | $37.0M | $17.0M | $3.8M | $437.0K | $78.0K | $209.0K | $771.0K |
| Free Cash Flow | -$117.7M | -$195.5M | -$243.5M | -$199.3M | -$87.2M | -$39.6M | -$29.1M | -$17.9M | -$16.8M |
| Share Buybacks | - | - | - | - | - | - | $0 | $0 | $4.0K |